Total Payments
$2.7M
2024 Payments
$394,068
Companies
48
Transactions
629
Payment Breakdown by Category
Consulting$2.1M (76.9%)
Research$584,717 (21.4%)
Travel$28,241 (1.0%)
Other$15,150 (0.6%)
Food & Beverage$3,215 (0.1%)
Education$800.00 (0.0%)
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Consulting Fee | $2.1M | 349 | 76.9% |
| Unspecified | $584,717 | 146 | 21.4% |
| Travel and Lodging | $28,241 | 46 | 1.0% |
| Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | $12,650 | 5 | 0.5% |
| Food and Beverage | $3,215 | 80 | 0.1% |
| Grant | $2,500 | 1 | 0.1% |
| Education | $800.00 | 2 | 0.0% |
Payments by Type
General
$2.2M
483 transactions
Research
$584,717
146 transactions
Top Paying Companies
| Company | Total | Records | Latest Year |
|---|---|---|---|
| Takeda Pharmaceuticals U.S.A., Inc. | $373,576 | 97 | $0 (2024) |
| UCB SA | $340,260 | 51 | $0 (2024) |
| AstraZeneca UK Limited | $247,565 | 65 | $0 (2024) |
| E.R. Squibb & Sons, L.L.C. | $189,813 | 31 | $0 (2024) |
| Alnylam Pharmaceuticals Inc. | $188,213 | 34 | $0 (2024) |
| JAZZ PHARMACEUTICALS INC. | $166,436 | 45 | $0 (2024) |
| Takeda Development Center Americas, Inc. | $134,901 | 26 | $0 (2017) |
| Sumitomo Pharma America, Inc. | $119,915 | 11 | $0 (2024) |
| AstraZeneca Pharmaceuticals LP | $118,213 | 22 | $0 (2024) |
| RedHill Biopharma Inc. | $93,504 | 6 | $0 (2023) |
Payment History by Year
| Year | Amount | Transactions | Top Company |
|---|---|---|---|
| 2024 | $394,068 | 68 | Sumitomo Pharma America, Inc. ($119,915) |
| 2023 | $270,306 | 53 | Alnylam Pharmaceuticals Inc. ($58,656) |
| 2022 | $397,384 | 78 | UCB SA ($81,000) |
| 2021 | $403,761 | 75 | UCB SA ($99,900) |
| 2020 | $336,774 | 51 | Takeda Pharmaceuticals U.S.A., Inc. ($125,299) |
| 2019 | $339,252 | 83 | Takeda Pharmaceuticals U.S.A., Inc. ($98,366) |
| 2018 | $234,623 | 127 | AstraZeneca UK Limited ($56,345) |
| 2017 | $362,194 | 94 | Takeda Development Center Americas, Inc. ($134,901) |
All Payment Transactions
629 individual payment records from CMS Open Payments — Page 1 of 26
| Date | Company | Product | Nature | Form | Amount | Type |
|---|---|---|---|---|---|---|
| 12/24/2024 | BeiGene USA, Inc. | BRUKINSA (Drug) | Consulting Fee | Cash or cash equivalent | $2,800.00 | General |
| Category: Oncology | ||||||
| 12/19/2024 | Sumitomo Pharma America, Inc. | — | Consulting Fee | Cash or cash equivalent | $12,837.50 | General |
| 12/10/2024 | E.R. Squibb & Sons, L.L.C. | Sotyktu (Drug) | Consulting Fee | Cash or cash equivalent | $2,700.00 | General |
| Category: Immunology | ||||||
| 12/02/2024 | JAZZ PHARMACEUTICALS INC. | XYREM (Drug) | Consulting Fee | Cash or cash equivalent | $4,893.75 | General |
| Category: NEUROLOGY | ||||||
| 11/15/2024 | AstraZeneca Pharmaceuticals LP | — | Consulting Fee | Cash or cash equivalent | $6,750.00 | General |
| 11/15/2024 | AstraZeneca Pharmaceuticals LP | — | Consulting Fee | Cash or cash equivalent | $3,937.50 | General |
| 11/12/2024 | E.R. Squibb & Sons, L.L.C. | — | Consulting Fee | Cash or cash equivalent | $8,268.75 | General |
| 11/08/2024 | E.R. Squibb & Sons, L.L.C. | Sotyktu (Drug) | Consulting Fee | Cash or cash equivalent | $2,700.00 | General |
| Category: Immunology | ||||||
| 10/29/2024 | E.R. Squibb & Sons, L.L.C. | Sotyktu (Drug) | Consulting Fee | Cash or cash equivalent | $10,125.00 | General |
| Category: Immunology | ||||||
| 10/15/2024 | BeiGene USA, Inc. | — | Consulting Fee | Cash or cash equivalent | $6,650.00 | General |
| 10/04/2024 | UCB SA | Bimzelx (Biological) | Consulting Fee | Cash or cash equivalent | $3,300.00 | General |
| Category: Immunology | ||||||
| 10/02/2024 | E.R. Squibb & Sons, L.L.C. | Sotyktu (Drug) | Consulting Fee | Cash or cash equivalent | $10,293.75 | General |
| Category: Immunology | ||||||
| 09/18/2024 | AstraZeneca UK Limited | SAPHNELO (Biological) | Consulting Fee | Cash or cash equivalent | $1,300.00 | General |
| Category: Inflammation and Autoimmunity | ||||||
| 09/16/2024 | E.R. Squibb & Sons, L.L.C. | Sotyktu (Drug) | Consulting Fee | Cash or cash equivalent | $8,437.50 | General |
| Category: Immunology | ||||||
| 09/12/2024 | Sumitomo Pharma America, Inc. | — | Consulting Fee | Cash or cash equivalent | $19,662.50 | General |
| 08/30/2024 | UCB SA | Bimzelx (Biological) | Consulting Fee | Cash or cash equivalent | $2,250.00 | General |
| Category: Immunology | ||||||
| 08/27/2024 | E.R. Squibb & Sons, L.L.C. | — | — | Cash or cash equivalent | $5,400.00 | Research |
| Study: Long-Term Study That Measures the Safety and Efficacy of Deucravacitinib (BMS-986165) in Participants With Psoriasis (POETYK PSO-LTE) | ||||||
| 08/26/2024 | Takeda Pharmaceuticals U.S.A., Inc. | — | — | Cash or cash equivalent | $9,116.25 | Research |
| Study: A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO ASSESS THE SAFETY, TOLERABILITY, PHARMACOKINETICS, AND PHARMACODYNAMICS OF SINGLE AND MULTIPLE DOSES OF TAK-861 IN HEALTHY ADULT AND ELDERLY SUBJECTS AND SUBJECTS WITH NARCOLEPSY TYPE 1 | ||||||
| 08/14/2024 | AstraZeneca Pharmaceuticals LP | — | Consulting Fee | Cash or cash equivalent | $5,250.00 | General |
| 08/14/2024 | AstraZeneca Pharmaceuticals LP | — | Consulting Fee | Cash or cash equivalent | $3,187.50 | General |
| 08/14/2024 | AstraZeneca Pharmaceuticals LP | — | Consulting Fee | Cash or cash equivalent | $2,325.00 | General |
| 08/02/2024 | UCB SA | Bimzelx (Biological) | Consulting Fee | Cash or cash equivalent | $2,550.00 | General |
| Category: Immunology | ||||||
| 08/01/2024 | Sumitomo Pharma America, Inc. | — | Consulting Fee | Cash or cash equivalent | $23,887.50 | General |
| 07/25/2024 | Sumitomo Pharma America, Inc. | — | Consulting Fee | Cash or cash equivalent | $13,000.00 | General |
| 07/12/2024 | UCB SA | Bimzelx (Biological) | Consulting Fee | Cash or cash equivalent | $720.00 | General |
| Category: Immunology | ||||||
Research Studies & Clinical Trials
| Study Name | Company | Amount | Records |
|---|---|---|---|
| THE?SPD489-323?PHASE 3, MULTICENTER, RANDOMIZED, DOUBLE-BLIND, PARALLEL-GROUP, PLACEBO-CONTROLLED, FLEXIBLE DOSE TITRATION, EFFICACY AND SAFETY STUDY OF SPD489 IN COMBINATION WITH AN ANTIDEPRESSANT IN THE TREATMENT OF ADULTS WITH MAJOR DEPRESSIVE DISORDER WITH INADEQUATE RESPONSE TO PROSPECTIVE TREATMENT WITH AN ANTIDEPRESSANT | Takeda Pharmaceuticals U.S.A., Inc. | $71,663 | 3 |
| A randomised double blind placebo controlled parallel group multicentre phase III study to evaluate the efficacy and safety of 2 doses of benralizumab MEDI 563 in patients with severe to very severe Chronic Obstructive Pulmonary Disease COPD with a history of COPD exacerbations GALATHEA | AstraZeneca UK Limited | $51,726 | 4 |
| The purpose of this study is to characterise longterm safety and tolerability of intravenous anifrolumab A Multicentre Randomised Double blind Placebo Controlled Phase 3 Extension Study to Characterise the Long term Safety and Tolerability of Anifrolumab in Adult Subjects With Active Systemic Lupus Erythematosus | AstraZeneca UK Limited | $34,973 | 4 |
| Phase 3B Study to Evaluate the Cardiovascular Safety of Febuxostat and Allopurinol in Gout Subjects With Cardiovascular Comorbidities and Hyperuricemia | Takeda Development Center Americas, Inc. | $32,631 | 4 |
| TV5600-CNS-20007 | Teva Pharmaceuticals USA, Inc. | $24,556 | 5 |
| A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PHASE 1 STUDY TO EVALUATE THE SAFETY, TOLERABILITY, AND PHARMACOKINETICS OF TAK-510 IN HEALTHY SUBJECTS | Takeda Pharmaceuticals U.S.A., Inc. | $23,400 | 4 |
| MYL-1701P | Mylan Inc. | $20,550 | 4 |
| A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO ASSESS THE SAFETY, TOLERABILITY, PHARMACOKINETICS, AND PHARMACODYNAMICS OF SINGLE AND MULTIPLE DOSES OF TAK-861 IN HEALTHY ADULT AND ELDERLY SUBJECTS AND SUBJECTS WITH NARCOLEPSY TYPE 1 | Takeda Pharmaceuticals U.S.A., Inc. | $19,904 | 2 |
| Long-Term Study That Measures the Safety and Efficacy of BMS-986165 in Participants With Psoriasis | E.R. Squibb & Sons, L.L.C. | $19,250 | 4 |
| LOWER: Lomitapide Observational Worldwide Evaluation Registry | Amryt Pharma Holdings Ltd | $17,950 | 10 |
| PH1 SRD NHV/PILOT FOOD EFFECT | Takeda Pharmaceuticals U.S.A., Inc. | $17,600 | 3 |
| A STUDY OF TAK-105 IN HEALTHY ADULTS | Takeda Pharmaceuticals U.S.A., Inc. | $16,738 | 2 |
| High dose ICS LABA 2ndController Study SIROCCO | AstraZeneca UK Limited | $14,925 | 3 |
| A Phase 3, Randomized, Double-blind, Placebo-controlled Study of Atrasentan in Patients With IgA Nephropathy at Risk of Progressive Loss of Renal Function | Novartis Pharmaceuticals Corporation | $13,650 | 1 |
| A STUDY TO ASSESS THE FREQUENCY AND CHARACTERISTICS OF WAKE AND SLEEP STATE TRANSITIONS OVER MULTIPLE NIGHTS IN SUBJECTS WITH NARCOLEPSY TYPE 1 COMPARED WITH HEALTHY SUBJECTS USING A PORTABLE ELECTROENCEPHALOGRAM DEVICE | Takeda Pharmaceuticals U.S.A., Inc. | $12,813 | 2 |
| A Multi-Center, Randomized, Double-Blind, Placebo- and Active Comparator-Controlled Phase 3 Study to Evaluate the Clinical Efficacy and Safety of BMS-986165 in Subjects with Moderate to Severe Psoriasis | E.R. Squibb & Sons, L.L.C. | $12,750 | 1 |
| A Multi-Center, Randomized, Double-Blind, Placebo- and Active Comparator-Controlled Phase 3 Study with an Induction Period Followed by a Randomized Maintenance Period to Evaluate the Clinical Efficacy and Safety of BMS-986165 in Subjects with Mod | E.R. Squibb & Sons, L.L.C. | $12,750 | 1 |
| A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PHASE 2 DOSE RANGING STUDY TO EVALUATE THE EFFICACY AND SAFETY OF 2 DOSE REGIMENS OF INTRAVENOUS TAK-954 FOR THE PROPHYLAXIS AND TREATMENT OF POSTOPERATIVE GASTROINTESTINAL DYSFUNCTION IN PATIENTS UNDERGOING LARGE- AND SMALL-BOWEL RESECTION | Takeda Pharmaceuticals U.S.A., Inc. | $12,263 | 4 |
| A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, SINGLE AND MULTIPLE RISING ORAL DOSE STUDY TO EVALUATE THE SAFETY, TOLERABILITY, PHARMACOKINETICS, AND PHARMACODYNAMICS OF TAK-994 IN HEALTHY SUBJECTS | Takeda Pharmaceuticals U.S.A., Inc. | $11,334 | 3 |
| A PHASE 1B RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, CROSSOVER STUDY OF A SINGLE INTRAVENOUS INFUSION DOSE OF TAK-925 IN PATIENTS WITH IDIOPATHIC HYPERSOMNIA | Takeda Pharmaceuticals U.S.A., Inc. | $10,125 | 1 |
| A RANDOMIZED PHASE 3 MULTICENTER OPEN-LABEL STUDY TO COMPARE THE EFFICACY OF TAK-788 AS FIRST-LINE TREATMENT VERSUS PLATINUM-BASED CHEMOTHERAPY IN PATIENTS WITH NON-SMALL CELL LUNG CANCER WITH EGFR EXON 20 INSERTION MUTATIONS | Takeda Pharmaceuticals U.S.A., Inc. | $10,125 | 1 |
| A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, MULTIPLE RISING ORAL DOSE STUDY TO EVALUATE THE SAFETY, TOLERABILITY, PHARMACOKINETICS, AND PHARMACODYNAMICS OF TAK-994 IN PATIENTS WITH NARCOLEPSY WITH OR WITHOUT CATAPLEXY (NARCOLEPSY TYPE 1 OR NARCOLEPSY TYPE 2) | Takeda Pharmaceuticals U.S.A., Inc. | $8,450 | 2 |
| The purpose of this study is to evaluate the efficacy and safety of an intravenous treatment regimen of anifrolumab versus placebo in adult subjects with moderately to severely active autoantibody positive systemic lupus erythematosus SLE | AstraZeneca UK Limited | $7,975 | 2 |
| The purpose of this study is to evaluate the efficacy and safety of an intravenous treatment regimen of two doses of anifrolumab versus placebo in adult subjects with moderately to severely active autoantibody positive systemic lupus erythematosus SLE | AstraZeneca UK Limited | $7,975 | 2 |
| STRATOS 1 Tralokinumab in Asthma Ph 3 Pivotal Study 1, A 52-Week, Multicentre, Randomized, Double-blind, Parallel Group, Placebo Controlled, Phase 3 Study to Evaluate the Efficacy and Safety of Tralokinumab in Adults and Adolescents with Asthma Inadequately Controlled on Inhaled Corticosteroid Plus Long-acting B2 Agonist | AstraZeneca UK Limited | $7,040 | 2 |
| A Multicenter, Multinational, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study to Evaluate the Efficacy and Safety of Laquinimod (0.5, 1.0 and 1.5 mg/Day) as Treatment in Patients With Huntington's Disease | Teva Pharmaceuticals USA, Inc. | $7,013 | 2 |
| Efficacy and Safety of Finerenone in Combination with SGLT2i | Bayer Healthcare Pharmaceuticals Inc. | $6,775 | 1 |
| BAY 948862, A parallel-group treatment, Phase 2, double-blind, three-arm study to assess efficacy and safety of finerenone plus empagliflozin compared with either finerenone or empagliflozin in participants with chronic kidney disease and type 2 diabetes | Bayer Healthcare Pharmaceuticals Inc. | $6,500 | 1 |
| A Phase 2 Randomized, Double-Blind, Placebo-Controlled, 2-Arm, Multi-center Study Comparing Tivozanib Hydrochloride in Combination With Paclitaxel Versus Placebo in Combination With Paclitaxel in the Treatment of Subjects With Locally Recurrent and/or Metastatic Triple Negative Breast Cancer | Astellas Pharma Global Development | $6,465 | 1 |
| TAK-994: RESEARCH ACTIVITIES ACROSS OREXIN PROGRAM | Takeda Pharmaceuticals U.S.A., Inc. | $6,338 | 1 |
| A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, THREE-PART PHASE 1 STUDY TO EVALUATE THE SAFETY, TOLERABILITY, AND PHARMACOKINETICS OF TAK-951 IN HEALTHY SUBJECTS | Takeda Pharmaceuticals U.S.A., Inc. | $5,963 | 1 |
| Long-Term Study That Measures the Safety and Efficacy of Deucravacitinib (BMS-986165) in Participants With Psoriasis (POETYK PSO-LTE) | E.R. Squibb & Sons, L.L.C. | $5,400 | 1 |
| Phase III PsA - A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Deucravacitinib in Participants with Active Psoriatic Arthritis who are Na ve to Biologic Disease-modifying Anti-rheumatic Drugs. | E.R. Squibb & Sons, L.L.C. | $5,400 | 1 |
| Lomitapide Peri & Post | Aegerion Pharmaceuticals, Inc. | $4,250 | 1 |
| Safety and Efficacy of Two Doses of Anifrolumab Compared to Placebo in Adult Subjects With Active Proliferative Lupus Nephritis | AstraZeneca UK Limited | $4,109 | 4 |
| A Randomized, Placebo-Controlled, Double-blind, Multicenter Study to Assess the Efficacy and Safety of Multiple Doses of BMS-986165 in Subjects With Active Psoriatic Arthritis (PsA) | E.R. Squibb & Sons, L.L.C. | $3,700 | 2 |
| A Randomized, Double-blind, Parallel Group, Placebo and Active Controlled, Multicenter Dose Ranging Study With the Beta-3 Agonist YM178 in Patients With Symptomatic Overactive Bladder | Astellas Pharma Global Development | $3,329 | 4 |
| A Study to Characterize the Pharmacokinetics, Pharmacodynamics, and Safety of Anifrolumab in Adult Type I Interferon Test High Systemic Lupus Erythematosus Subject With Active Skin Manifestations | AstraZeneca UK Limited | $3,300 | 1 |
| A Prospective, Double-Blind, Randomized, Two-Period Crossover, Multi-Center Study to Evaluate the Tolerability and Patient Preference Between Myrbetriq and Detrol LA in Subjects with Overactive Bladder (OAB) | Astellas Pharma Global Development | $2,446 | 1 |
| A Multi-Center, Randomized, Double-Blind, Placebo- and Active Comparator-Controlled Phase 3 Study with an Induction Period Followed by a Randomized Maintenance Period to Evaluate the Clinical Efficacy and Safety of BMS-986165 in Subjects with Moderate to | E.R. Squibb & Sons, L.L.C. | $2,400 | 1 |
| LOWER:LomitapideObservational Worldwide Evaluation Registry (LOWER) | Chiesi USA, Inc. | $2,100 | 1 |
| A 3-PART, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, MULTIPLE RISING DOSE STUDY TO EVALUATE THE SAFETY, TOLERABILITY, PHARMACOKINETICS AND PHARMACODYNAMICS OF TAK-925 IN HEALTHY VOLUNTEERS AND PATIENTS WITH NARCOLEPSY | Takeda Pharmaceuticals U.S.A., Inc. | $1,584 | 1 |
| A FIRST-IN-HUMAN, TWO-PART STUDY TO ASSESS THE SAFETY, TOLERABILITY, PHARMACOKINETICS, AND PHARMACODYNAMICS OF TAK-925 IN HEALTHY ADULT AND ELDERLY VOLUNTEERS AND PATIENTS WITH NARCOLEPSY | Takeda Pharmaceuticals U.S.A., Inc. | $1,584 | 1 |
| A PHASE 1B, 4-PERIOD CROSSOVER, PLACEBO-CONTROLLED, RANDOMIZED, SINGLE DOSE STUDY TO EVALUATE THE SAFETY, TOLERABILITY, PHARMACOKINETICS, AND PHARMACODYNAMICS OF TAK-925 IN SLEEP-DEPRIVED HEALTHY ADULTS UTILIZING MODAFINIL AS AN ACTIVE COMPARATOR | Takeda Pharmaceuticals U.S.A., Inc. | $1,584 | 1 |
| This is a multiple dose randomised parallel double blind double dummy multicentre and multinational Phase III study to determine the efficacy and safety of Aclidinium bromide Formoterol fumarate compared with individual components and placebo and Aclidinium bromide compared with Placebo when administered to patients with stable Chronic Obstructive Pulmonary Disease COPD | AstraZeneca UK Limited | $1,250 | 1 |
| Evaluate Cardiovascular Outcomes Following Treatment with Alogliptin in Addition to Standard of Care in Subjects with Type 2 Diabetes | Takeda Development Center Americas, Inc. | $1,057 | 3 |
| Phase 3B Study to Evaluate the Cardiovascular Safety of Febuxostat and Allopurinol in Gout Subjects With Cardiovascular Comorbidities and Hyperuricemia | Takeda Pharmaceuticals U.S.A., Inc. | $917.56 | 4 |
| A Randomized, Double-Blind, Parallel Group, Placebo and Active Controlled, Multicenter Study to Assess the Efficacy and Safety of Mirabegron in Subjects With Symptoms of Overactive Bladder | Astellas Pharma Global Development | $889.98 | 4 |
| A Randomized, Double-blind, Parallel-group, Placebo-controlled Study in Patients With Symptomatic Overactive Bladder | Astellas Pharma Global Development | $889.98 | 5 |
| A Phase III, Randomized, Double-Blind, Parallel Group, Placebo Controlled, Multicenter Study to Assess the Efficacy and Safety of Mirabegron in Subjects With Symptoms of Overactive Bladder | Astellas Pharma Global Development | $889.97 | 4 |
| A Randomized, Double-Blind, Parallel-Group, Placebo- and Active-Controlled, Multi-center Study to Evaluate the Efficacy, Safety and Tolerability of Combinations of Solifenacin Succinate and Mirabegron Compared to Solifenacin Succinate and Mirabegron Monotherapy in the Treatment of Overactive Bladder | Astellas Pharma Global Development | $871.28 | 2 |
| An Investigational Study to Evaluate Experimental Medication BMS-986165 Compared to Placebo in Participants With Plaque Psoriasis (POETYK-PSO-3) in Mainland China, Taiwan, and South Korea (POETYK-PSO-3) | E.R. Squibb & Sons, L.L.C. | $600.00 | 1 |
| Phase III Study of YM178 - A Placebo-controlled, Double-blind, Group Comparison Study in Patients With Overactive Bladder | Astellas Pharma Global Development | $585.05 | 4 |
| A Randomized, Double-Blind, Parallel Group, Active Controlled, Multi-center Long-term Study to Assess the Safety and Efficacy of the Beta-3 Agonist Mirabegron (YM178) 50 mg qd and 100 mg qd in Subjects With Symptoms of Overactive Bladder | Astellas Pharma Global Development | $445.71 | 1 |
| A Phase 2, Randomized, Double-blind, Parallel Group, Placebo Controlled, Multi-center Study to Evaluate the Urodynamics and Safety of YM178 in Male Subjects With Lower Urinary Tract Symptoms (LUTS) and Bladder Outlet Obstruction (BOO) | Astellas Pharma Global Development | $445.69 | 1 |
| Long-term Study of YM178: Long Term Study of YM178 in Subjects With Overactive Bladder | Astellas Pharma Global Development | $445.69 | 1 |
| Long-term Study of YM178 Long Term Study of YM178 in Subjects With Overactive Bladder | Astellas Pharma Global Development | $444.27 | 3 |
| A Phase 2, Randomized, Double-blind, Parallel Group, Placebo Controlled, Multi-center Study to Evaluate the Urodynamics and Safety of YM178 in Male Subjects With Lower Urinary Tract Symptoms LUTS and Bladder Outlet Obstruction BOO | Astellas Pharma Global Development | $444.26 | 3 |
| A Randomized, Double-Blind, Parallel Group, Active Controlled, Multi-center Long-term Study to Assess the Safety and Efficacy of the Beta-3 Agonist Mirabegron YM178 50 mg qd and 100 mg qd in Subjects With Symptoms of Overactive Bladder | Astellas Pharma Global Development | $444.26 | 3 |
| A Prospective, Double-Blind, Randomized, Two-Period Crossover, Multi-Center Study to Evaluate the Tolerability and Patient Preference Between Myrbetriq and Detrol LA in Subjects With Overactive Bladder OAB | Astellas Pharma Global Development | $324.46 | 2 |
| STRATOS 2 Tralokinumab in Asthma Ph 3 Pivotal Study 2, A 52-Week, Multicentre, Randomized, Double-blind, Parallel Group, Placebo Controlled, Phase 3 Study to Evaluate the Efficacy and Safety of Tralokinumab in Adults and Adolescents with Asthma Inadequately Controlled on Inhaled Corticosteroid Plus Long-acting B2 Agonist | AstraZeneca UK Limited | $218.39 | 2 |
| A Multicentre Randomized Double blind Parallel Group Placebocontrolled Phase III Efficacy and Safety Study of Benralizumab MEDI 563 Added to High dose Inhaled Corticosteroid Plus Long acting 2 Agonist in Patients with Uncontrolled Asthma CALIMA | AstraZeneca UK Limited | $200.00 | 1 |
About Dr. William White, MD
Dr. William White, MD is a Hypertension Specialist healthcare provider based in Farmington, Connecticut. This provider has been registered with the National Plan and Provider Enumeration System (NPPES) since 07/07/2005. The National Provider Identifier (NPI) number assigned to this provider is 1760489546.
According to the Centers for Medicare & Medicaid Services (CMS) Open Payments database, Dr. William White, MD has received a total of $2.7M in payments from pharmaceutical and medical device companies, with $394,068 received in 2024. These payments were reported across 629 transactions from 48 companies. The most common payment nature is "Consulting Fee" ($2.1M).
Ad
Practice Information
- Specialty Hypertension Specialist
- Location Farmington, CT
- Active Since 07/07/2005
- Last Updated 06/15/2012
- Taxonomy Code 207RH0005X
- Entity Type Individual
- NPI Number 1760489546
Products in Payments
- Uloric (Drug) $142,110
- XYWAV (Drug) $130,149
- Movantik (Drug) $86,043
- Sotyktu (Drug) $74,419
- MOVANTIK (Drug) $58,286
- ONPATTRO (Drug) $51,941
- SAPHNELO (Biological) $44,528
- FASENRA (Drug) $25,681
- Bimzelx (Biological) $25,410
- LEMTRADA (Drug) $24,859
- Laquinimod (Drug) $24,556
- NORTHERA (Drug) $22,103
- Nucynta (Drug) $19,650
- Aciphex (Drug) $16,298
- XYREM (Drug) $15,406
- Veltassa (Drug) $14,841
- Mirabegron (Drug) $14,611
- XYOSTED (Drug) $13,850
- SD809-TD (Drug) $13,800
- Kerendia (Drug) $13,275
Explore
Data Sources
Provider data from NPPES. Payment data from CMS Open Payments. Medicare data from CMS Medicare Provider Utilization. All data is public and updated periodically.